Department of General Surgery, Lanzhou University Second Hospital, Lanzhou 730030, China.
Hepato-Biliary-Pancreatic Institute, Lanzhou University Second Hospital, Lanzhou 730030, China.
Can J Gastroenterol Hepatol. 2020 Dec 5;2020:8839098. doi: 10.1155/2020/8839098. eCollection 2020.
Portal hypertension is a series of syndrome commonly seen with advanced cirrhosis, which seriously affects patient's quality of life and survival. This study was designed to access the efficacy and safety of selective esophagogastric devascularization in the modified Sugiura procedure for patients with cirrhotic hemorrhagic portal hypertension.
Sixty patients with hepatitis B cirrhotic hemorrhagic portal hypertension and meeting the inclusion criteria were selected and randomly divided by using computer into the selective modified Sugiura group (sMSP group, = 30) and the modified Sugiura group (MSP group, = 30). The primary endpoint measurement is the postoperative rebleeding rate. Secondary endpoint measurements included free portal venous pressure, liver Child-Pugh score, liver volume, portal vein width and blood flow velocity, survival rate, quality of life, and dysphagia as well as other complications one year postoperatively. This trial is registered with ChiCTR, number ChiCTR2000033468.
There was no statistically significant difference in rebleeding rates within one year after surgery between patients in the sMSP and MSP groups ( = 0.11, =0.73). In comparison with the MSP group, the Child-Pugh score of liver function in the sMSP group significantly increased ( = 6.4, =0.04) and the incidence of dysphagia was significantly reduced ( = 6.23, =0.01) one year after surgery. There was a statistically significant difference in the quality of life between the two groups. However, there were no statistically significant differences in free portal venous pressure (MD = -3.44, 95% CI: -7.87 to 0.98, =0.12), postoperative liver volume (3 months: MD = -258.81, 95% CI: -723.21 to 205.57, =0.24; 1 year: MD = -320.12, 95% CI: -438.43 to 102.78, =0.16), postoperative portal vein width (3 months: MD = -0.06, =0.50; 1 year: MD = 0.17, =0.21), portal vein flow velocity (3 months: MD = 1.64, =0.21; 1 year: MD = -1.19, =0.57), 1-year survival rate ( = 1.01, =0.31), and other complications between the two groups.
Selective esophagogastric devascularization in the modified Sugiura procedure may not lower the incidence of rebleeding in the short term based on our findings. However, it may significantly improve quality of life of patients with cirrhotic hemorrhagic portal hypertension, improve liver function, and reduce postoperative dysphagia.
门静脉高压是肝硬化晚期常见的一系列综合征,严重影响患者的生活质量和生存。本研究旨在评估改良 Sugiura 手术中选择性贲门胃底血管离断术(selective esophagogastric devascularization,SEGD)治疗肝硬化出血性门静脉高压的疗效和安全性。
本研究纳入了符合纳入标准的 60 例乙型肝炎肝硬化出血性门静脉高压患者,并使用计算机将其随机分为选择性改良 Sugiura 组(selective modified Sugiura procedure,sMSP 组,n=30)和改良 Sugiura 组(modified Sugiura procedure,MSP 组,n=30)。主要终点测量指标为术后再出血率。次要终点测量指标包括自由门静脉压、肝功能 Child-Pugh 评分、肝体积、门静脉宽度和血流速度、1 年生存率、生活质量、术后吞咽困难等并发症。本研究已在 ChiCTR 注册,注册号 ChiCTR2000033468。
sMSP 组和 MSP 组患者术后 1 年内再出血率无统计学差异( = 0.11,=0.73)。与 MSP 组相比,sMSP 组患者术后肝功能 Child-Pugh 评分明显升高( = 6.4,=0.04),术后吞咽困难发生率明显降低( = 6.23,=0.01)。两组患者的生活质量存在统计学差异。然而,两组患者的自由门静脉压(MD=-3.44,95%CI:-7.87 至 0.98,=0.12)、术后肝体积(3 个月:MD=-258.81,95%CI:-723.21 至 205.57,=0.24;1 年:MD=-320.12,95%CI:-438.43 至 102.78,=0.16)、门静脉宽度(3 个月:MD=-0.06,=0.50;1 年:MD=0.17,=0.21)、门静脉血流速度(3 个月:MD=1.64,=0.21;1 年:MD=-1.19,=0.57)、1 年生存率( = 1.01,=0.31)以及其他并发症发生率之间无统计学差异。
根据我们的研究结果,改良 Sugiura 手术中选择性贲门胃底血管离断术在短期内可能不会降低再出血的发生率。然而,它可能显著改善肝硬化出血性门静脉高压患者的生活质量,改善肝功能,减少术后吞咽困难。